Evidence map›Paper›PMID 28785591›Full record

ReviewBioMed research international2017

The Management of Cardiovascular Risk through Epigenetic Biomarkers.

Laurent Metzinger, Stefano de Franciscis, Raffaele Serra

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05134597 (Th17- Gene Expression Profile in Patients With Chronic Venous Leg Insufficiency and Ulcers), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05134597 unknown statusnot on this mapstarted 2021, after this paper: background citation

Th17- Gene Expression Profile in Patients With Chronic Venous Leg Insufficiency and Ulcers: Genetical and Clinical Outcomes

TypeobservationalSponsorUniversity of CatanzaroRan2021 to 2022Enrolled30ConditionsGenetic Predisposition to Disease, Inflammation, Venous Leg UlcerArmsGenetic assessment
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Laurent MetzingerCURS, Laboratoire INSERM U1088, Université de Picardie Jules Verne, chemin du Thil, 80025 Amiens Cedex 1, France.ORCID 0000-0002-7636-8480
Stefano de FranciscisInteruniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0001-9365-4609
Raffaele SerraInteruniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0003-4477-7412
Magna Graecia University · ITInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic sciences study heritable changes in gene expression not related to changes in the genomic DNA sequence. The most important epigenetic mechanisms are DNA methylation, posttranslational histone modification, and gene regulation by noncoding RNAs, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Cardiovascular diseases (CVD) are responsible for at least one-third of premature deaths worldwide and represent a heavy burden of healthcare expenditure. We will discuss in this review the most recent findings dealing with epigenetic alterations linked to cardiovascular physiopathology in patients. A particular focus will be put on the way these changes can be translated in the clinic, to develop innovative and groundbreaking biomarkers in CVD field.

Indexed as

EpigenomicsBiomarkersCardiovascular DiseasesDNA MethylationGenetic TherapyHumansRisk FactorsBiomarkers

Identifiers

PMID28785591
PMCPMC5530445
OpenAlexW2734802264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.